<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94011">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01802255</url>
  </required_header>
  <id_info>
    <org_study_id>ECSEVO-LT-011</org_study_id>
    <secondary_id>2011-002555-34</secondary_id>
    <nct_id>NCT01802255</nct_id>
  </id_info>
  <brief_title>Sevoflurane- Safety in Long-term Sedation Procedures</brief_title>
  <official_title>Study of the Safety of Administration of Sevoflurane for Long-term Critically Ill Patients Sedation Undergoing Mechanical Ventilation. Prospective, Controlled, Randomized, Multicenter, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>F Javier Belda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients needing intensive care often require sedative drugs to reduce anxiety and agitation
      during ventilator care and invasive therapeutic and diagnostic procedures. At present there
      is no optimal sedative agent for these patients. The most commonly used sedative agents in
      intensive care units are midazolam and propofol. Both drugs have side effects of clinical
      importance.

      At present, a viable alternative to intravenous sedation is inhalatory sedation.
      Sevoflurane, as other inhaled anesthetic agents, is sedative in low doses. A new simplified
      method of administration of isoflurane or sevoflurane has been developed. The Anesthetic
      Conserving Device is a modified heat-moisture exchanger (HME) that permits direct infusion
      of sevoflurane to the airway, where it is vaporized in an evaporator rod in the device.

      However, the use of sevoflurane is limited to anesthesia and sedation lasting no more than
      12 hours, since the possible renal problems posed by inorganic fluoride in prolonged
      operations remain the subject of controversy.

      The primary aim (and primary hypothesis) of the current trial is to determine whether
      sevoflurane can be administered as a sedative drug for more than 48 hours without clinically
      relevant physiopathological effects on kidney and liver function.

      Other end-points of the trial are to evaluate the quality of sedation of sevoflurane, in
      terms of sedation control, the rapidity and predictability of awakening, and the incidence
      of delirium in critical care patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Maintenance of renal function.</measure>
    <time_frame>Baseline.  Posteriorly, every 12 hours for the full length of sedation.  After sedation, every 24 hours up to one week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurements in plasma: creatinine and cystatin levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of liver function</measure>
    <time_frame>Baseline.  Posteriorly, every 12 hours for the full length of sedation.  After sedation, every 24 hours up to one week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurements in plasma: SGOT (aspartate aminotransferase, AST), SGPT (alanine aminotransferase, ALT), LDH (lactate dehydrogenase) alkaline phosphatase, conjugated and total bilirubin, cholesterol, triglycerides, albumin, total proteins, electrolytes and glycogen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of fluoride</measure>
    <time_frame>Baseline.  Posteriorly, every 12 hours for the full length of sedation.  After sedation, every 24 hours up to one week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine evolutionary plasmatic levels of fluorides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of delirium</measure>
    <time_frame>Baseline.  Posteriorly, every 12 hours for the full length of sedation.  After sedation, every 24 hours up to one week</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incidence of delirium will be evaluated by the CAM-ICU method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Poisoning by Inhaled Anaesthetic</condition>
  <condition>Fluoride Poisoning</condition>
  <condition>Recovery From Sedation</condition>
  <condition>Renal Function</condition>
  <condition>Hepatic Function</condition>
  <arm_group>
    <arm_group_label>Inhalatory sedation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevoflurane given via AnaConDa for sedation minimum 48 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam given intravenously for sedation minimum 48 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Treatment group: Inhalatory sedation with sevoflurane via AnaConDa.</description>
    <arm_group_label>Inhalatory sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Control Group: Intravenous sedation with midazolam.</description>
    <arm_group_label>Intravenous sedation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signing of the informed consent document (patient or relatives).

          -  Patient age 18 years or older.

          -  Expected minimum duration of sedation: 48 hours.

        Exclusion Criteria:

          -  Chronic renal failure treated with replacement therapy (hemodialysis or peritoneal
             dialysis).

          -  Acute kidney injury in Stage 3 of AKIN classification

          -  Grade C hepatic Child-Pugh classification

          -  Established Acute Respiratory Distress Syndrome (ARDS).

          -  Central nervous system pathology with cognitive disorders that not allow performing
             the test of the study: severe dementia, Alzheimer's disease, depression,
             schizophrenia, acute stroke.

          -  Head trauma with Glasgow &lt;12.

          -  Patient treated with antiepileptic drugs that must be maintained during the study
             period

          -  Patients requiring the use of neuromuscular blocking agents during the infusion of
             study drug, except for the insertion of the endotracheal tube.

          -  Epidural or spinal analgesia

          -  Allergy or known hypersensitivity to any of the study drugs

          -  Patients with known or suspected genetic susceptibility to malignant hyperthermia

          -  Previous participation in this trial

          -  Participation in another clinical trial within 4 weeks prior to selection.

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Soro, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luciano Aguilera, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Basurto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Soria, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Asistencial de León</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Acosta, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>F Javier Belda, MD, PhD</last_name>
    <email>fjbelda@uv.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F Javier Belda, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Kong KL, Bion JF. Sedating patients undergoing mechanical ventilation in the intensive care unit--winds of change? Br J Anaesth. 2003 Mar;90(3):267-9. PubMed PMID: 12594134.</citation>
    <PMID>12594134</PMID>
  </reference>
  <reference>
    <citation>Röhm KD, Wolf MW, Schöllhorn T, Schellhaass A, Boldt J, Piper SN. Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery. Intensive Care Med. 2008 Sep;34(9):1683-9. doi: 10.1007/s00134-008-1157-x. Epub 2008 May 24.</citation>
    <PMID>18500419</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 4, 2013</lastchanged_date>
  <firstreceived_date>February 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion para la Investigacion del Hospital Clinico Universitario de Valencia</investigator_affiliation>
    <investigator_full_name>F Javier Belda</investigator_full_name>
    <investigator_title>Prof. Dr. F Javier Belda</investigator_title>
  </responsible_party>
  <keyword>Inhalatory sedation</keyword>
  <keyword>Sevoflurane</keyword>
  <keyword>AnaConDa</keyword>
  <keyword>Nephrotoxicity</keyword>
  <keyword>Hepatotoxicity</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Propofol</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoride Poisoning</mesh_term>
    <mesh_term>Poisoning</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
